Terms ending in 2044
Every in-force patent on Merck Sharp and Dohme LLC's record whose computed term ends in 2044, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,780,845 | Arginase Inhibitors and Methods of Use In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 12,643,904 | RIPK1 Inhibitors and Methods of Use In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 12,709,595 | Novel Synthetic Pathway to Belzutifan In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 12,565,494 | Inhibitors of Human Respiratory Syncytial Virus and Metapneumovirus In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 12,548,316 | Multi-Dimension Unified Swin Transformer for Lesion Segmentation In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 12,643,882 | Inhibitors of Human Respiratory Syncytial Virus and Metapneumovirus In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 12,782,372 | Robot Task Scheduler with Verified Audit Trail In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 12,466,840 | Small Molecule Inhibitors of Kras Proteins In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 12,697,308 | Novel Thermostable Lipid Nanoparticle and Methods of Use Thereof In force · High confidence | Merck | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
8 of these are in force and held by Merck Sharp and Dohme LLC.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.